Merck initiates long-term study on Sotatercept for Pulmonary Arterial Hypertension
Merck is conducting a long-term follow-up study to assess the safety and tolerability of Sotatercept in patients with PAH.
Phase III
Pulmonary Arterial Hypertension / Targeted Therapy
Status
Active
Sponsor
Merck
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of a long-term study on Sotatercept by Merck is significant as it aims to establish the drug's safety and tolerability in treating Pulmonary Arterial Hypertension (PAH). Successful outcomes could solidify Sotatercept's position in the PAH treatment landscape, impacting competitive dynamics and treatment options.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include patient enrollment rates and interim safety results from the long-term follow-up study.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.